Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review.

Despite widespread mass rollout programs, the rapid spread of the SARS-CoV-2 Omicron variant called into question the effectiveness of the existing vaccines against infection, hospitalization, severity, and mortality compared to previous variants. This systematic review summarizes and compares the effectiveness of the COVID-19 vaccines, with respect to the above outcomes in adults, children, and adolescents. A comprehensive literature search was undertaken on several databases. Only 51 studies met our inclusion criteria, revealing that the protection from primary vaccination against Omicron infection is inferior to protection against Delta and Alpha infections and wanes faster over time. However, mRNA vaccine boosters were reported to reestablish effectiveness, although to a lower extent against Omicron. Nonetheless, primary vaccination was shown to preserve strong protection against Omicron-associated hospitalization, severity, and death, even months after last dose. However, boosters provide more robust and longer-lasting protection against hospitalizations due to Omicron as compared to only primary series.

Physical Versus Digital Orthognathic Surgical Planning.

OBJECTIVE: Orthognathic occlusal repositioning wafers could be constructed virtually and 3D printed. This paper assessed the accuracy of a suggested virtual model to the conventionally established Glasgow model surgery. DESIGN: Prospective study of the orthognathic surgery models digitally. PARTICIPANTS: Seven patients who received bi-maxillary orthognathic surgeries for correction of dentofacial deformities. METHODS: The patients were clinically assessed and their cone beam cmputerized tomography (CBCT) studied. Model surgery of each patient was performed conventionally using face-bow and semi-adjustable articulator. Same plan was executed virtually using Mimics (Materialise, Leuven, Belgium) and 3Matic (Materialise, Leuven, Belgium). Conventionally fabricated acrylic wafers as well as 3D printed wafers were CBCT scanned with the casts reflecting the archived repositioning dictated by the wafers. Paired sample t test was performed to compare accuracy between intermediate and final occlusal repositioning wafers within conventional and virtual technique groups. RESULTS: The mean deviation in intermediate wafer group was 0.64 ± 0.33 mm; whereas the mean deviation in final wafer group was 0.53 ± 0.10 mm. Paired sample t test showed that there was no statistically significant difference in mean deviation between both groups ( P = 0.403). CONCLUSIONS: This virtual surgical wafer achieves a similar level of accuracy to the conventional Glasgow model surgery.

First Successful Large-Scale Introduction of an Enhanced Recovery after Bariatric Surgery (ERABS) Program in the Middle East: The Results and Lessons Learned of Tawam Hospital/Johns Hopkins, a Tertiary Governmental Center in the UAE.

BACKGROUND: Although enhanced recovery after bariatric surgery (ERABS) has proven to be safe and cost-effective, this concept is relatively new in the Middle East. METHODS: A retrospective analysis of consecutive registered cohorts of patients who underwent primary and purely laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB) were compared before introduction of ERABS (2010-2014) and after ERABS (2015-2017) at Tawam Hospital/Johns Hopkins, the UAE. RESULTS: A total of 462 eligible bariatric patients (LSG 414 and LRYGB 48) were operated on before and 1602 (LSG 1436 and LRYGB 166) after introduction of the ERABS. Significant improvements of mean patient time of the patient being within the OR for LSG (from 2:27 to 1:23 min, p = 0.000) and LRYGB (from 3:17 to 1:59 min, p = 0.000) were achieved when comparing pre-ERABS with after introduction of ERABS. Furthermore, there was a significant decrease in LOS in both LSG (from 3.2 to 1.5 days, p = 0.000) and in LRYGB (from 3.5 to 1.7 days, p = 0.000). Major (CD classification III-IV) complications decreased significantly in LSG (from 13.8 to 0.8%, p = 0.000) and were similar in LRYGB (from 4.2% to 3.0%, p = NS). The readmission rate for LSG (from 2.9 to 2.6%, p = NS) or LRYGB (from 0 to 4.8%, p = NS) and the reoperation rates after LSG (from 0.7 to 0.5%, p = NS) and LRYGB (from 0 to 2.4%, p = NS) did not differ between both groups following introduction of ERABS. CONCLUSIONS: Implementation of a standardized ERABS program in the Middle East is feasible and safe and leads to reduced LOS and OR times.